1. Home
  2. BXSL vs BLTE Comparison

BXSL vs BLTE Comparison

Compare BXSL & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Secured Lending Fund of Beneficial Interest

BXSL

Blackstone Secured Lending Fund of Beneficial Interest

N/A

Current Price

$24.77

Market Cap

5.5B

Sector

Finance

ML Signal

N/A

Logo Belite Bio Inc

BLTE

Belite Bio Inc

N/A

Current Price

$161.58

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BXSL
BLTE
Founded
2018
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
6.0B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
BXSL
BLTE
Price
$24.77
$161.58
Analyst Decision
Buy
Strong Buy
Analyst Count
10
7
Target Price
$27.18
$198.00
AVG Volume (30 Days)
1.6M
153.2K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
12.87%
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$492.11
P/E Ratio
$164.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.47
$62.18
52 Week High
$30.20
$200.00

Technical Indicators

Market Signals
Indicator
BXSL
BLTE
Relative Strength Index (RSI) 59.18 51.24
Support Level $23.08 $158.32
Resistance Level $24.69 $172.02
Average True Range (ATR) 0.47 6.82
MACD 0.06 -0.74
Stochastic Oscillator 78.42 27.85

Price Performance

Historical Comparison
BXSL
BLTE

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: